Antisense Therapeutics Limited
ATHJF · OTC
6/30/2024 | 12/30/2023 | 6/30/2023 | 12/30/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 47.3% | 10.5% | 120.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 98.9% | 96.4% | 98.7% | 96.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -405.4% | -394.4% | -562.1% | -1,066.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -405.9% | -395.2% | -562.1% | -1,068.8% |
| EPS Diluted | -0.007 | -0.007 | -0.009 | -0.008 |
| % Growth | -6.1% | 28.3% | -17.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |